How is Brentuximab dosed?
The recommended dosage for adult patients with Hodgkin lymphoma, sALCL, or pcALCL is 900 mg administered as an intravenous infusion over 30 to 60 minutes, every 3 weeks. For patients with classical Hodgkin lymphoma, the dosage is 300 mg administered as an intravenous infusion over 30 to 60 minutes, followed by chemotherapy, every 21 days for up to 6 cycles. Please consult with your healthcare provider for personalized dosing instructions based on your specific medical condition.
What is the dosage form of Brentuximab?
Brentuximab injection is available in the form of a powder for solution.
What medications are contraindication with Brentuximab?
Brentuximab may interact with other medications. It is important to inform your healthcare professional about all the medications you are taking, including over-the-counter medicines, vitamins, and herbal products, as they might interact with brentuximab. Always consult your doctor before starting, stopping, or changing any medication while receiving brentuximab treatment.
How is Brentuximab administered?
Brentuximab is administered by a healthcare professional in a medical setting, such as a hospital or clinic. It is given through a needle inserted into a vein. The injection may be given alone or in combination with other medications, depending on the medical condition being treated.
What are common precautions when taking Brentuximab?
Common precautions when taking brentuximab include informing your doctor about any allergies, other medications you are taking, and any pre-existing medical conditions. This medication should be used under the direct supervision of a healthcare professional. It is important to follow the dosage instructions provided by your doctor carefully. If you experience any side effects, consult your doctor for medical advice. The safety and efficacy of brentuximab in pediatric patients have not been established.